Nuvectis Pharma, Inc. 4

Vice President of Finance Michael J. Carson received an equity award of 30,000 shares of restricted common stock of Nuvectis Pharma, Inc. (NVCT).

On August 3, 2026, Nuvectis Pharma, Inc. Vice President of Finance Michael J. Carson was granted 30,000 shares of restricted common stock, which will fully vest on August 3, 2027, contingent on his continued service with the company. The Form 4 shows this as an acquisition of common stock, increasing his direct beneficial ownership to 230,118 shares in total, including the newly granted restricted shares. No transaction price was reported, consistent with this being an equity compensation award rather than an open-market trade, and no additional sales or purchases were disclosed in the filing.

Filing Facts

CIK

1875558

Ticker

NVCT

Form

4

Source Type

fda

Accession

0001104659-26-091279

Alert Tier

5